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Infectious and parasitic diseases represent the third cause of 
cancer worldwide. A number of infectious and parasitic agents 
have been suspected or recognized to be associated with human 
cancers, including DNA viruses, such as papillomaviruses (sev-
eral HPV types), herpesviruses (EBV and KSHV), polyomaviruses 
(SV40, MCV, BK, and JCV), and hepadnaviruses (HBV); RNA 
viruses, such as flaviviruses (HCV), defective viruses (HDV), 
and retroviruses (HTLV-I, HTLV-II, HIV-1, HIV-2,HERV-K, and 
XMRV); bacteria, such as H. pylori, S. typhi, S. bovis, Bartonella, 
and C. pneumoniae; protozoa, such as P. falciparum; trematodes, 
such as S. haematobium, S. japonicum, S. mansoni, O. viverrini, 
O. felineus, and C. sinensis. Each one of the chronic infections 
with H. pylori, HPV, and HBV/HCV is responsible for approxi-
mately the 5% of all human cancers. The primary prevention 
of infection-related cancers is addressed both to avoidance and 
eradication of chronic infections and to protection of the host 
organism. Vaccines provide fundamental tools for the prevention 
of infectious diseases and related cancers. The large-scale appli-
cation of the HBV vaccine has already shown to favorably affect 
the epidemiological burden of primary hepatocellular carcinoma, 
and HPV vaccines have specifically been designed in order to pre-
vent cervical cancer and other HPV-related cancers. The second-
ary prevention of infection-associated cancers has already found 
broad applications in the control of cervical cancer. Detection 
of early gastric cancer by endoscopy has been applied in Asian 
countries. Avoidance of local relapses, invasion, and metastasis 
may be achieved by applying tertiary prevention, which targets 
specific mechanisms, such as angiogenesis.
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Epidemiology of infection-associated 
cancers 
Global burden
After dietary factors and tobacco smoke, infectious 
diseases represent the third leading cause of cancer 
worldwide. The population attributable fraction, which 
indicates the proportion of cancers associated with in-
fectious and parasitic diseases, was estimated to be the 
10% in the US population in 1981 [1], 10-20% in the UK 
population in 1998 [2], 3.6% in the French population 
in 2000 [3], 5% (range of acceptable estimates: 4-15%) 
in the UK population in 2005 [4], and 29.4% (31.7% in 
men and 25.3% in women) in the Chinese population in 
2005 [5]. In the world population, it was estimated to be 
the 15.6% in 1990 [6], 17.8% in 2002 [7], and 16.1% in 
2008 [8] . The last figure would correspond to about 2 
million new cases of infection-related cancers diagnosed 
all over the world in 2008 [8].
The above estimates in the world population take into 
account the attributable fraction relative to the infections 
categorized in Group 1 by the International Agency for 
Research on Cancer (IARC), highlighting the infectious 
and parasitic agents for which there is sufficient evi-
dence for carcinogenicity to humans [9]. Figure 1, which 
summarizes the results of two recent estimates  [7,  8], 
shows, at a glance, the paramount importance of chronic 
infections in the etiology of cancer on a global scale. 
In particular, it appears that the chronic infections with 
Helicobacter pylori, human papillomaviruses (HPV), 
and hepatitis B (HBV) and C (HCV) viruses are each 
responsible for approximately the 5% of all human can-
cers and, altogether, they accounted for the 15.6% of hu-
man cancers worldwide in 2002 [7] and for the 14.7% 
in 2008 [8].
There are sharp differences in the epidemiological im-
pact of infection-associated cancers between developing 
countries and developed countries, where the population 
attributable fraction has been estimated to be the 26.3% 
and 7.7% of cases, respectively [7] . These differences 
are due to geographical variations in the endemicity of 
infectious and parasitic agents associated with cancer as 
well as to the distinctive availability of preventive and 
therapeutic means towards both cancers and the related 
infectious diseases. Interestingly, lung cancer, colorectal 
cancers, breast cancer, and prostate cancer are, in terms 
of incidence, the 4 leading cancers in most geographical 
regions in the world [10]. The large majority of the ex-
ceptions to the above set of 4 cancers can be ascribed to 
cancers associated with infectious and parasitic diseases, 
which appear to contribute substantially to the dispari-
ties in cancer incidence between developed countries 
and developing countries.
A number of chronic viral, bacterial and protozoan in-
fections and trematode infestations have been associated 
with human cancers affecting a variety of anatomical 
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sites. Table I reports a list of these agents, along with 
their categorization by IARC concerning the evidence of 
carcinogenicity to humans. 
Viral infections
Among DNA viruses, a dozen of HPV types, includ-
ing types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 
59, have been allocated by IARC in Group 1, as their 
carcinogenicity to humans has been sufficiently dem-
onstrated. Other HPV types are categorized either in 
Group 2A (probably carcinogenic), Group 2B (possibly 
carcinogenic) or Group 3 (inadequate evidence of car-
cinogenicity to humans). The overall fraction of cancer 
attributable to HPV infection was estimated to be the 
5.2% in 2002 [7] and the 4.8% in 2008 [8]. The persis-
tent infection of the uterine cervix by HPV is responsi-
ble for virtually the 100% of cervical cancers, although 
other factors may interact with HPV in the etiology of 
cervical cancer, which is the third leading cancer in the 
world female population in terms of mortality. In addi-
tion, HPV can target other sites in the anogenital region 
of women and/or men (vulva, vagina, penis, and anus), 
in the upper aerodigestive tract (mouth and oropharynx), 
and in the skin.
Herpesviridae include two important cancer-associated 
viruses, both of which are categorized in IARC Group 1. 
Each of them has been associated with almost the 1% of 
all human cancers (Fig. 1). One is the Epstein-Barr virus 
(EBV), or human herpersvirus 4 (HHV4), which causes 
infectious mononucleosis during adolescence and young 
adulthood while it is associated, in certain geographical 
areas, with several types of lymphoma. The most impor-
tant EBV-related cancer is Burkitt’s lymphoma, which 
is a quite common childhood cancer in sub-Saharan Af-
rica. The most likely interpretation for the distinctive 
pathogenic spectrum of EBV in different geographical 
areas is a possible association with malaria where the 
Burkitt’s lymphoma is prevalent (see below). In addition 
to lymphomas, EBV is associated with nasopharyngeal 
carcinoma, presumably in connection with genetic fac-
tors. The other cancer-associated virus of this family is 
the Kaposi’s sarcoma-associated herpesvirus (KHSV), 
or human herpesvirus 8 (HHV8), which has been dis-
covered in patients affected by acquired immunodefi-
ciency syndrome (AIDS).
Four viruses belonging to the family of polyomaviridae, 
including SV40, MCV, BK, and JCV, have been evalu-
ated for their association with human cancers [11]. SV40 
(simian virus 40) has been suspected to be associated 
with mesothelioma. While its carcinogenicity to humans 
appears to be inadequate, there is sufficient evidence for 
SV40 carcinogenicity in experimental animals, also in 
association with asbestos. Nevertheless, SV40 has been 
allocated by IARC in Group 3, indicating that this virus 
is not classifiable as to its carcinogenicity to humans. 
MCV (Merkel cell virus) has been associated with MCC 
(Merkel cell carcinoma). Being its carcinogenicity not 
supported by studies in experimental animals, it has been 
Fig. 1. Fractions of cancers attributable to infectious agents categorized in IArC group 1, as related to the total number of cancer cases in 
the world population in 2002 [7] (dark grey columns) and 2008 [8] (light grey columns).
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categorized as probably carcinogenic to humans (Group 
2A). Two other polyomaviruses, BKV and JCV, were 
classified as possibly carcinogenic to humans (Group 
2B) because the evidence for carcinogenicity to animals 
is sufficient, whereas their carcinogenicity to humans 
was evaluated to be inadequate. Both BK and JC are the 
initials of the patients from whom the viruses were iso-
lated for the first time. In particular, BKV was found to 
induce a broad variety of tumors, also depending on the 
administration route, in hamsters, rats, and mice, but hu-
man data for prostate cancer and other types of cancer 
are inconsistent. Likewise, brain tumors were induced 
in monkeys and hamsters injected intracerebrally with 
JVC, but there is no clear association between JCV in-
fection in humans and cancers [11]. 
HBV and HCV are hepatotropic viruses whose infection 
may evolve into chronic viral hepatitis. They are quite 
different viruses, being HBV a DNA virus belonging to 
the family of hepadnaviridae, whereas HCV is an RNA 
virus belonging to the family of flaviviridae. Both virus-
es are allocated in IARC Group 1 and, collectively, they 
were estimated to be responsible for the 4.9% of cancers 
in the world population in 2002 [7] and for the 4.7% in 
2008 [8]. They have been associated with the 85.5% of 
cases of hepatocellular carcinomas (HCC), the 54.4% of 
which is attributable to HBV and the 31.1% is attribut-
able to HCV [7]. The HBV nucleocapsid encloses the 
circular viral DNA, which is not fully double-stranded, 
and a DNA polymerase that has reverse transcriptase ac-
tivity. A variety of mechanisms, spanning from integra-
tion of HBV DNA into the cellular genome to induction 
of cellular oncogenes by HBV gene products (e.g., HBx-
Ag), deletion or mutation of tumor suppressor genes, and 
liver cirrhosis with inflammation, necrosis and regenera-
tion , have been proposed as mechanisms involved in 
HBV carcinogenesis. Our studies have highlighted the 
importance of synergisms with chemical hepatocarcino-
gens (e.g., aflatoxin B1 and food pyrolysis products), 
whose metabolic activation is enhanced in the liver both 
of humans infected with HBV and of woodchucks in-
fected with WHV (woodchuck hepatitis virus), which 
shares similarities with HBV  [12-15]. The hepatitis D 
virus (HDV), or hepatitis delta antigen, having a circular 
RNA genome and needing the surface antigen of HBV 
(HBsAg) to establish infection in humans either as a co-
infection or a superinfection, was classified in Group 3 
by IARC several years ago [16], as the demonstration of 
HDV contribution to HCC induction by HBV was not 
adequate. However, more recently it has been suggested 
that the risk of hepatocellular carcinoma is higher when 
HBV is superinfected with HDV [17].
The RNA strands of retroviruses are complexed with 
reverse transcriptase and are thus transcribed into a dou-
ble-stranded DNA that is inserted into the host genome, 
an obligatory step for their replication  [18]. HTLV-I 
(human T-cell lymphotropic virus type 1) has been asso-
ciated with adult T cell leukemia/lymphoma and it is al-
located in IARC Group 1, whereas HTLV-II is in Group 
3. HIV-1 (human immunodeficiency virus type 1) is the 
etiological agent of AIDS (acquired immune deficiency 
syndrome), which, due to immunodeficiency, has been 
associated with several human cancers and especially 
with KHSV-related Kaposi’s sarcoma and non-Hodg-
kin’s lymphoma. HIV-2 is possibly carcinogenic to hu-
mans. Two other retroviruses have been suspected to be 
associated with human cancers. One is HERV-K (hu-
Tab. I. pathogenic agents suspected or recognized to be associated 
with human cancers, and their allocation in IArC groups according to 
the evidence of carcinogenicity to humans.
Pathogenic agent1 IARC Group2
DNA viruses
hpv, alpha types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59
1
hpv, alpha type 68 2A
hpv, alpha types 26, 30, 34, 53, 66, 67, 69, 
70, 73, 82, 85 and 97,and beta types 5 and 8
2B
hpv, alpha types 6 and 11, other beta and 
gamma types
3
eBv (hhv4) 1
KShv (hhv8) 1
Sv40 3
mCv 2A
BKv 2B
JCv 2B
hBv 1
RNA viruses
hCv 1
hdv 3
hTLv-I 1
hTLv-II 3
hIv-1 1
hIv-2 2B
herv-K NA
Xmrv NA
Bacteria
helicobacter pylori 1
Salmonella typhi NA
Streptococcus bovis NA
Bartonella species NA
Chlamidophila pneumoniae NA
Protozoa
plasmodium falciparum 2A
Trematodes
Schistosoma haematobium 1
Schistosoma japonicum 2B
Schistosoma mansoni 3
Opistorchis viverrini 1
Opistorchis felineus 3
Chlonorchis sinensis 1
1 See text for acronyms.
2 group 1, sufficient evidence of carcinogenicity to humans; group 2A, 
probably carcinogenic; group 2 B, possibly carcinogenic; group 3, inad-
equate evidence of carcinogenicity to humans; NA, not available.
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man endogenous retrovirus), which may be involved in 
breast carcinogenesis [19], and the other one is XMRV 
(xenotropic murine leukemia-related virus), a chimeric, 
laboratory-derived gammaretrovirus that, interestingly, 
arose from the recombination of two endogenous mouse 
viruses. XMRV was suspected to be associated with 
prostate cancer [20].
Bacterial infections
The prototype of cancer-associated bacteria is H. pylori, 
which is categorized in IARC Group 1 and was respon-
sible for the 5.5% of cancers in the world in 2002  [7] 
and for the 5.2% in 2008 [8]. It has been estimated to 
account for the 63.4% [7] or 80.0% [19] of gastric can-
cers, specifically non-cardia gastric cancer. In addition, 
the chronic infection of the stomach with this bacterium 
is associated with MALT (mucosa-associated lymphoid 
tissue lymphoma). The intriguing issue is that about 
two-thirds of the world population, with some geograph-
ic variations, are carriers of H. pylori, and luckily only 
a small fraction of colonized individuals develop gastric 
cancer. We demonstrated that both bacterial and host 
gene polymorphisms affect oxidative stress and DNA 
damage, which is believed to represent a key mechanism 
in the pathogenesis of gastric cancer [21].
Among other bacteria, Salmonella typhi and Streptococ-
cus bovis have been suspected of being associated with 
gallbladder carcinoma and colorectal cancer, respective-
ly [22]. The persistent infection of erythrocytes and en-
dothelial cells with Bartonella can trigger angiogenesis 
and lead to vascular tumor formation in humans, and 
Chlamydophila pneumoniae has been suspected of be-
ing associated with lung cancer [23]. 
Protozoan infections
Plasmodium falciparum infection in holoendemic areas 
is probably carcinogenic to humans (IARC Group 2A) 
because, in the absence of any adequate evidence in ex-
perimental animals, there is limited evidence for an as-
sociation between malaria caused by infection with that 
protozoan species and cancer. In particular, it is well 
demonstrated that P. falciparum reactivates EBV there-
by contributing to Burkitt’s lymphoma etiology [11].
Trematode infestations
Some of the flatworms belonging to the Schistosoma ge-
nus, also known as blood flukes, have been investigated 
for their association with human cancers, especially in 
certain geographical areas. There is sufficient evidence 
for the ability of S. haematobium to cause urinary blad-
der cancer, whereas S. japonicum is possibly associated 
with colorectal and liver cancers, and there is inadequate 
evidence for the carcinogenicity of S. mansoni. Among 
the flatworms known as river flukes, there is sufficient 
evidence for the role of Opistorchis viverrini in inducing 
cholangiocarcinoma, while the evidence for Opistorchis 
felineus is evaluated to be inadequate. The same cancer 
is associated with infestation of the human common bile 
duct and gallbladder with the Chinese liver fluke (Clon-
orchis sinensis) [9].
Prevention strategies for infection-
associated cancers
Primary prevention
The primary prevention of infection-related cancers is 
addressed both to avoid and eradicate chronic infections 
and infestations and to defend the host organism at a time 
when a subject is still apparently healthy. Therefore, the 
first line of defence is to prevent the infectious and para-
sitic disease, a goal that can be pursued by means of both 
aspecific and specific measures.
Vaccines play a fundamental role among the specific 
tools available to prevent some cancer-related infec-
tions. While the development of candidate vaccines 
against certain agents, such as HCV, HIV, H. pylori, 
and P. falciparum, is still in progress and suffers from 
technical problems, other vaccines are extensively used 
worldwide and hold great promises in cancer prevention. 
One of them is the hepatitis B vaccine, which has been 
introduced into routine infant immunization programs 
since 1992. The impact of anti-HBV vaccination on 
HCC epidemiology has already been demonstrated in 
Taiwan, where the universal HBV vaccination program, 
launched in 1984, reduced the prevalence of HBV to ap-
proximately one-tenth. In parallel, evidence was provid-
ed that HCC incidence was decreased as a consequence 
of the vaccination in children aged 6-14 years and, later 
on, also in early adulthood [24]. Failures to prevent HCC 
depended mostly on the unsuccessful control of HBV 
infection of maternal origin. Besides early vaccination 
of infants, administration of hepatitis B immunoglobulin 
immediately after birth, and even antiviral agent during 
the third trimester of pregnancy are possible strategies 
to block mother-to-infant transmission of HBV and to 
prevent HCC [25].
The HBV vaccine is the first example of cancer-preven-
tive vaccine in humans, proving evidence that prevention 
of an infectious disease can prevent the related cancer. 
On the other hand, HPV vaccines are the first example 
of vaccines that have specifically been designed to pre-
vent HPV-related cancers in humans. In fact, these vac-
cines, containing the HPV envelope protein L1 obtained 
by recombinant DNA techniques  [23], target the HPV 
types responsible for the majority of cervical cancers 
and of non-cervical cancers as well. It can been foreseen 
that, together with secondary prevention, HPV vaccines 
will be successful in further reducing the burden of CIN 
(cervical intraepithelial neoplasia) and of HPV-related 
cancers.
Since infections need to become persistent in order to 
trigger the development of cancers, whichever is their 
mechanism of action, a further primary prevention strat-
egy is to avoid chronicization of the disease. Thus, it is 
intriguing that the therapy of an infectious and parasitic 
disease becomes a tool to prevent the associated can-
cer. Besides a broad variety of drugs available to cure 
specific infectious diseases, examples of this kind of 
prevention include the HAART (high active antiretro-
viral therapy) for HIV infections, the new drugs avail-
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able for the treatment of chronic hepatitis B and C, and 
the treatments to eradicate H. pylori infection in healthy 
asymptomatic subjects. For instance, in the Shandong 
Intervention Trial, two weeks of antibiotic treatment for 
H. pylori reduced the incidence of both precancerous 
gastric lesions and gastric cancer [26].
Furthermore, it should be taken into account that cancers 
are multifactorial in origin and that, besides infectious 
agents, other factors may contribute to the risk of devel-
oping the same cancers. Such a circumstance involves 
the implementation of integrated strategies for the pri-
mary prevention of these cancers. An extreme example 
is provided by HPV infections. Although HPV infections 
cause almost the 100% of cervical cancer cases, HPV 
can interact with other co-factors, such as tobacco smok-
ing, hormonal contraceptive use, intake of nutrients, 
and co-infections with HSV (Herpes Simplex Virus) or 
Chlamydia trachomatis [27]. Other examples of interac-
tions are either between different infectious agents, e.g., 
between HIV and KSHV in the pathogenesis of Kapo-
si’s sarcoma or between EBV and P. falciparum in the 
pathogenesis of Burkitt’s lymphoma, or between infec-
tious agents and chemical carcinogens. For instance, the 
synergism between HBV and chemical hepatocarcino-
gens requires integrated strategies addressed to prevent 
chronic hepatitis B, to avoid exposures to chemical car-
cinogens, and to reinforce the body defence mechanisms 
by means of dietary and pharmacological agents.
Secondary prevention
In case primary prevention fails avoiding the occurrence 
of a neoplastic lesion and the carcinogenic process starts 
its course, it is still possible to apply secondary preven-
tion. Its goal is to detect a preneoplastic or a neoplastic 
lesion at an early stage and to intervene timely in order 
to stop progression of cancer.
An infection-associated cancer, the HPV-related cer-
vical cancer, provides the most classical example of 
secondary prevention. The cytological analysis of epi-
thelial cell smears, introduced by George Papanicolau 
more than 80 years ago, meets all the criteria requested 
for an oncological screening, from the epidemiological 
relevance of the disease to the poor invasivity of cell 
collection, fair performance of the test, low cost, and 
availability of a therapy to cure the disease. The large-
scale application of the Pap test has remarkably reduced 
the burden of cervical cancer in all developed countries 
and has driven a wedge between different geographical 
areas. More recently, the HPV DNA testing, which ana-
lyzes the DNA of high risk HPV (HR HPV) in cervi-
cal cells, has been introduced and proposed to replace 
the Pap test as a first-screen method. This molecular 
approach detects an ongoing infection with HR HPV, 
which just testifies the risk of developing cervical cancer 
rather than an HPV-related cytological alteration. Thus, 
it is more sensitive but less specific and it needs confir-
mation by means of a cytological test and, if necessary, 
of colposcopy and biopsy.
Another example of secondary prevention applied to an 
infection-associated cancer is early gastric cancer, in 
which the disease is limited to mucosa and submucosa, 
so that removal of the lesion confers a survival rate af-
ter 5 years of 90%. Regression of premalignant lesions 
has been demonstrated after H. pylori eradication. Asian 
countries have implemented national screening pro-
grams for the detection of early gastric cancer, but in 
Western countries mass screening is not cost-effective 
and strategy has been directed to screen symptomatic 
individuals who are at higher risk of gastric cancer [28]. 
Serology testing for biomarkers such as pepsinogen, an-
ti-H. pylori antibody and gastrin have been studied as an 
alternative to endoscopy [28].
Tertiary prevention
In the framework of the oncological patient manage-
ment, tertiary prevention is addressed to cancer patients 
after therapy and it has the goal toprevent local relapses, 
invasion, and metastasis  [29]. It can be pursued either 
by treating the cancer-related infection, e.g., by using 
antiviral agents to prevent recurrences in HBV-positive 
patients who have been cured for HCC [25], and/or by 
treating the neoplastic lesion. Besides traditional cyto-
static drugs, the pharmacological armamentarium avail-
able for cancer therapy and tertiary prevention has been 
strengthened by introducing a variety of “smart drugs” 
that, rather than aspecifically kill cancer cells, try to tar-
get specific molecular mechanisms involved in cancer 
development and growth. A promising approach is to 
inhibit angiogenesis, which is a crucial mechanism in 
several infection-related cancers, by targeting VEGF 
(vascular endothelial growth factor) and other pro-angi-
ogenetic factors [30]. Examples are HCC, having a hy-
pervascular nature [31], bartonella-induced vascular tu-
mors, and HIV/ KSHV-related Kaposi’s sarcoma, which 
is a highly vascularized cancer. We demonstrated that 
the oral administration of the antioxidant agent NAC 
(N-acetylcysteine) reduced tumor growth in nude mice 
xenotransplanted with human KS cells and, in some 
cases, there was a complete regression of the neoplastic 
mass [32].
Conclusions
The prevention of infection-associated cancers would 
be expected to control an important fraction of human 
cancers. Compared with cancers having a non-infectious 
nature, in principle these cancers would appear to be 
more easily avoidable because, besides the other strate-
gies applicable to cancer prevention, it is sufficient to 
protect the body from exogenous pathogenic agents and 
to hamper the persistence of infections. Indeed, both 
primary prevention and secondary prevention measures 
have already proven to be successful in fighting certain 
cancers associated with infectious and parasitic diseases, 
which is highlighted by the sharp disparities between 
developed and developing countries in the incidence 
of these cancers. Future objectives in the prevention of 
infection-associated cancers include the improvement 
of our scientific knowledge about the mechanisms in-
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volved, the development of new tools for the control of 
both infectious diseases and associated cancers, and the 
application of preventive measures on a global scale in 
order to fill the gap existing among different regions in 
the world.
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